British-Indian cardiologist Dr. Aseem Malhotra has accused the WHO of losing its independence and advised the Indian government to disregard it. Malhotra claimed that huge pharma companies finance 65% of drug regulators including the FDA, creating a conflict of interest.
Eminent British-Indian cardiologist Dr. Aseem Malhotra has said that the WHO has lost its independence and advised the Indian government to ignore its advice on many topics and leave the global health authority. Malhotra, who lectured on “The Corporate Capture of Medicine and Public Health” at AIIMS, told PT that regulators do not independently assess pharmacological data.
FDA, which evaluates pharmaceuticals, receives 65% of its funding from big pharma. UK regulators receive 86% funding from pharma corporations. A major conflict of interest. Patients and doctors believe these organizations independently evaluate data, but they do not. We cannot proceed until commercial conflicts of interest are removed from health policies and decision-making “Malhotra stated.
Malhotra claimed the WHO has lost its independence.
“The WHO receives 70% commercial funding…. The WHO is not independent if it receives industry or special interest financing, therefore the Indian government should ignore its advise. He claimed commercial entities will profit by deception, not your health.
Malhotra said the WHO should be independently supported so governments, doctors, and the public may trust its recommendations are based on the greatest research.
He added, “What that means is that the information doctors use to make decisions for patients, specifically when it comes to drug prescription, has been biased and corrupted by big pharma whose only interest is to produce profit for the shareholders and not to give you the best treatment.” Most doctors are unaware that medical knowledge is under commercial control.
Malhotra argued that the most famous medical publications always report drug clinical trial findings that drastically misrepresent safety and benefits.
“What I am promoting is ethical, evidence-based medical practice and for that, there has to be ethical, evidence-based clinical trials that take into consideration individual patient preferences and values,” stated.
Malhotra said that less than 10% of big pharmaceutical companies’ new treatments in the last two decades are actually revolutionary.
Change the drug’s chemicals, make it more expensive, change the name, and rebrand it. They will profit and move on. Only 10% of new drugs in the last two decades have been actually useful and improved. Imagine the wasteful spending “He said.
Malhotra further claimed that the rollout, compulsion, and mandating of the Covishield and Pfizer anti-COVID vaccinations revealed the system’s biggest failings, where business motivations trump humans even if they are maimed and killed
Scientists without financial ties to product producers should design and assess clinical trials. Second, drug regulators should be prohibited from accepting pharmaceutical funds. He claimed the glaring conflict of interest has had catastrophic results.
Conclusion
British-Indian cardiologist Dr. Aseem Malhotra has accused the WHO of losing its independence and advised the Indian government to ignore its advice on many matters. Malhotra said that big pharma companies finance 65% of drug regulators including the FDA, a clear conflict of interest. He believed the WHO should be independently supported to give governments, clinicians, and the public trust in its evidence-based recommendations.
Malhotra also noted big pharma’s prejudice and corruption of medical expertise, which prioritizes shareholder profits before patient care. He claimed that drug regulators should be prohibited from accepting pharma funds and that experts should design and assess clinical studies without financial ties to medication manufacturers.
Malhotra has questioned the rollout, pressure, and mandating of the Covishield and Pfizer anti-COVID vaccines, saying commercial motivations trump deaths and maiming. He urged that experts without financial ties to product producers design and analyze clinical studies and that drug regulators be banned from accepting pharma financing.
